Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0352W HIGH $5.55
Volume
950.41 K
Value Traded
3.85 M
Short % Float
4.55%
-9.38%Week
-37.92%1 Month
-16.8%3 Month
+18.71%6 Month
-89.68%5 Year
-89.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
169.32 M
EPS (TTM)
-1.06
P/E Ratio
-
Ent. Value
136.32 M
Total Shares
83.41 M
Float Shares
102.83 M
Insiders
13.92%
Institutions
32.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PYXS Catalyst Timeline
Dated clinical, regulatory and corporate events for Pyxis Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pyxis Oncology, Inc.
256Total events
14Upcoming
57Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Pricing of up to $282.6M public offering of common stock, pre-funded warrants and common warrants
◆Oral Presentationmicvotabart pelidotinPresentation
Webcast to present updated clinical data from Phase 1 monotherapy study of MICVO in 2L+ R/M HNSCC
second-line and beyond recurrent/metastatic head and neck squamous cell carcinomasource ↗
▲Topline Readoutmicvotabart pelidotinClinical Data
Updated Phase 1 monotherapy data in 2L+ R/M HNSCC (data cutoff August 18, 2026)
2L+ recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)source ↗
◆Additional Datamicvotabart pelidotinClinical Data
Webcast to present updated Phase 1 monotherapy data for MICVO in 2L+ R/M HNSCC
second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC)source ↗
◆Topline ReadoutMICVOClinical Data
Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC
recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)source ↗
◆Topline Readoutmicvotabart pelidotinClinical Data
Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC
2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinomasource ↗
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference fireside chat
◆Poster PresentationMICVOPresentation
Poster presentation of preclinical data for maMICVO in HNSCC at AACR 2026
head and neck squamous cell carcinoma (HNSCC)source ↗
◆Timing GuidanceMICVOPresentation
Updated data from Phase 1/2 combination dose escalation study of MICVO + pembrolizumab in 1L/2L+ R/M HNSCC
recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumorssource ↗
◆Topline ReadoutMICVOClinical Data
Updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC
2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinomasource ↗
▲Poster PresentationMICVOPresentation
Presented new preclinical data at AACR 2026 supporting MICVO as monotherapy and in combination with pembrolizumab
Head and Neck Squamous Cell Carcinomasource ↗
●Poster Presentationmicvotabart pelidotinPresentation
Preclinical data presentation at AACR 2026 Annual Meeting
Head and Neck Squamous Cell Carcinomasource ↗
◆Topline Readoutmicvotabart pelidotinClinical Data
Updated data from Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026
recurrent/metastatic head and neck squamous cell carcinomasource ↗
▲Runway Guidance UpdateCorporate
Cash runway expected through data milestones and into second half of 2026
▲Enrollment CompleteMICVOTrial
Completed target enrollment in Phase 1 Part 2 monotherapy dose expansion study
2L+ R/M HNSCCsource ↗
▲Enrollment Completemicvotabart pelidotinTrial
Completed target enrollment in Phase 1 Part 2 monotherapy dose expansion study
2L+ R/M HNSCCsource ↗
◆Topline Readoutmicvotabart pelidotinClinical Data
Preliminary data from MICVO monotherapy expansion cohort (prior EGFRi and PD-1 inhibitor therapy)
recurrent and metastatic head and neck squamous cell carcinomasource ↗
◆Timing Guidancemicvotabart pelidotinPresentation
Preliminary data from monotherapy expansion (prior EGFRi/PD-1) expected 1H26
recurrent and metastatic head and neck squamous cell carcinomasource ↗
▲Topline Readoutmicvotabart pelidotinClinical Data
Positive preliminary Phase 1/2 data for MICVO in combination with pembrolizumab in 1L/2L+ R/M HNSCC
recurrent/metastatic head and neck squamous cell carcinomasource ↗
●Oral Presentationmicvotabart pelidotinPresentation
Company webcast and conference call to review preliminary Phase 1 data
recurrent/metastatic head and neck squamous cell carcinomasource ↗
▲FDA Feedback Receivedmicvotabart pelidotinFDA Meeting
FDA alignment on clinical trial design for planned pivotal monotherapy study in 2L+ R/M HNSCC
recurrent/metastatic head and neck squamous cell carcinomasource ↗
▲Topline Readoutmicvotabart pelidotinClinical Data
Preliminary positive combination results shared
1L/2L+ R/M HNSCCsource ↗
●Protocol Amendmentmicvotabart pelidotinTrial
Dose cap implemented for high body weight patients
2L+ R/M HNSCCsource ↗
◆Poster Presentationmicvotabart pelidotinPresentation
Translational data poster at AACR-NCI-EORTC 2025
solid tumorssource ↗
◆Poster Presentationmicvotabart pelidotinPresentation
Translational data poster at ESMO 2025
solid tumorssource ↗
◆Topline Readoutmicvotabart pelidotinClinical Data
Preliminary data from Phase 1 monotherapy dose expansion study of MICVO in 2L/3L R/M HNSCC and Phase 1/2 combination dose escalation study of MICVO and KEYTRUDA in 1L/2L+ R/M HNSCC
recurrent and metastatic head and neck squamous cell carcinomasource ↗
▲Poster Presentationmicvotabart pelidotinPresentation
Presented translational data at ESMO 2025 and AACR-NCI-EORTC
solid tumorssource ↗
▲FDA Feedback Receivedmicvotabart pelidotinFDA Meeting
FDA feedback and alignment on clinical trial design for planned pivotal monotherapy study in 2L+ R/M HNSCC
2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinomasource ↗
◆Oral PresentationPresentation
2nd Annual ADC and Novel Conjugates Partnering and Investment Summit company presentation
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference fireside chat
▲Milestone PaymentsuvemcitugCorporate
Received $2.8 million milestone payment from Simcere for approval of suvemcitug in China
oncologysource ↗
◆Topline Readoutmicvotabart pelidotinClinical Data
Preliminary data from MICVO monotherapy expansion cohort (prior platinum and PD-1 inhibitor therapy)
recurrent and metastatic head and neck squamous cell carcinomasource ↗
◆Timing GuidancePYX-201Presentation
Preliminary data from dose expansion cohorts expected across 2H 2025 and 1H 2026
multiple solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How PYXS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | PYX-201 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$53M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.3x
rNPV / MCap
Top 42%
Micro Cap(rank 278 of 660)
Percentile Rank
Pyxis Oncology, Inc. faces pipeline headwinds (39/100), with $1.1B risk-adjusted pipeline value, led by APX005M in Locally Advanced Rectal Adenocarcinoma (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APX005M Small moleculeCompletedNCT03165994 | Esophageal Cancer | Phase 2 | COMPLETED | 34 | Feb 21, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every PYXS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| micvotabart pelidotin Fast Track | recurrent/metastatic head and neck squamous cell carcinoma | Phase 1 | 2026-09-09 | confirmed objective response rate: 36%; disease control rate: 94%; median progression free survival: 6.2 months; 12 month overall survival probability: 79%Read More | Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GordonMD Global Investments LP10% Owner | Buy | 5,517,000 15,541,909 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PYXS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Palo Alto Investors LP | 0.4 % (100 %) | 2.60 M | 864.28 K | -14.47% ( -146.23 K) |
PYXS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PYXS ranks across every disease it competes in
Competitive Position is a premium feature
See how PYXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPYXS News
PYXSPyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Pyxis Oncology has successfully closed a public offering, raising approximately $110 million upfront, with potential total proceeds of $282.6 million. The offering included common stock and pre-funded warrants linked to clinical milestones. The funds will support the advancement of their lead candidate, MICVO, in ongoing clinical trials for difficult-to-treat cancers.
Read more →PYXS▼ -19.7%on this newsshared move
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Pyxis Oncology has announced the pricing of a public offering aimed at raising up to $282.6 million. The offering includes shares of common stock and warrants, with expected gross proceeds of around $110 million initially. The funds will be used to advance their lead clinical program, MICVO, through critical milestones, including a planned Phase 3 trial. The offering is set to close on or about October 1, 2026.
Read more →PYXS▼ -19.7%on this newsshared move
Pyxis Oncology Announces Proposed Public Offering
Pyxis Oncology has announced a proposed public offering of common stock and pre-funded warrants to raise funds for advancing its lead clinical program, MICVO. The offering is contingent upon stockholder approval for an amendment to increase authorized shares. Proceeds will support a Phase 3 trial and other corporate purposes. The company is focused on developing therapeutics for difficult-to-treat cancers.
Read more →PYXS▼ -13.1%on this news
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology has announced positive updated data from its Phase 1 study of micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head and neck squamous cell carcinoma. The study showed a 36% confirmed objective response rate and a 94% disease control rate, with median progression-free survival of 6.2 months. The company plans to advance MICVO into a pivotal Phase 3 trial, expected to start in mid-2027.
Read more →PYXS▼ -13.1%on this newsshared move
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology will host a live webcast on September 9, 2026, to present updated data from its Phase 1 study of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma. The presentation will cover the scientific rationale, treatment implications, and updated efficacy and safety results. Dr. Alan L. Ho will participate in the event.
Read more →PYXSPyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
Pyxis Oncology has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026. Civik, who has been Interim CEO since February 2026, will lead the company as it approaches significant clinical milestones for its lead candidate, MICVO. John Flavin, the co-founder, transitions to Lead Independent Director, ensuring continuity in leadership.
Read more →PYXS▲ +6.2%on this news· ran to +20% by day 3
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology, Inc. will participate in three upcoming investor conferences, featuring Interim CEO Tom Civik. The conferences include the Wells Fargo 21st Annual Healthcare Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. The company is focused on developing its lead candidate, MICVO, for difficult-to-treat cancers.
Read more →PYXS▼ -5.3%on this news
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology reported its financial results for Q2 2026, highlighting advancements in its MICVO clinical programs. The company is on track to present updated data from its Phase 1 studies in Fall 2026 and Q4 2026. A successful private placement raised approximately $50 million, extending the cash runway into mid-2027. The company aims to address unmet needs in head and neck cancer treatment.
Read more →PYXS▲ +5.2%on this news
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Pyxis Oncology has announced a private placement financing expected to raise up to $114 million to support its lead program, MICVO. The financing will extend the company's cash runway into the second quarter of 2027, allowing for further clinical development and patient follow-up. Updated data from ongoing studies is anticipated in late 2026.
Read more →PYXS▼ -15.6%on this news· ran to -27% by day 3
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology has reported its first quarter 2026 financial results, highlighting advancements in its MICVO clinical program. Key clinical data updates are projected for mid-2026 and the second half of 2026, focusing on monotherapy and combination therapies for recurrent/metastatic head and neck cancer. The company also presented promising preclinical data at the AACR Annual Meeting 2026, indicating potential efficacy of MICVO. However, it continues to face financial challenges, with a reported net loss of $23.3 million in the quarter.
Read more →PYXSPyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology has appointed Nelson Azoulay as Chief Business Officer, bringing over 15 years of experience in corporate strategy and business development in the biopharma industry. His expertise in antibody-drug conjugates will be instrumental as he leads the corporate development strategy and pursues opportunities to advance the company’s lead clinical asset, MICVO. Both the company and Azoulay expressed excitement about addressing unmet needs in treating head and neck cancer, particularly through clinical milestones expected in the near future.
Read more →PYXSPyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Pyxis Oncology announced new preclinical data demonstrating the anti-tumor efficacy of maMICVO, a mouse analog of MICVO, in a head and neck squamous cell carcinoma (HNSCC) model. The data indicated that maMICVO not only inhibited tumor growth when used alone but also worked synergistically with anti-PD-1 to achieve greater tumor control. These findings support the ongoing clinical development of MICVO as both a monotherapy and a combination treatment for R/M HNSCC patients. The new data will be presented at the AACR Annual Meeting 2026 in San Diego.
Read more →PYXSPyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology has completed target enrollment in its Phase 1 study of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma. The company reported positive preliminary data, including a 46% confirmed objective response rate for MICVO as monotherapy. Financial results for 2025 showed a net loss of $79.6 million, with revenues declining to $13.9 million. The company expects to report updated data from ongoing studies in mid and late 2026.
Read more →PYXSPyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Pyxis Oncology has appointed Thomas Civik as Interim CEO following the departure of Lara S. Sullivan. Civik, a seasoned biotechnology executive, aims to maintain leadership continuity while the Board searches for a permanent CEO. The company remains focused on advancing its lead program, micvotabart pelidotin (MICVO), in ongoing clinical trials.
Read more →PYXS▼ -48.7%on this news· ran to -68% by day 3
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Pyxis Oncology has announced promising preliminary Phase 1 data for its antibody-drug conjugate, micvotabart pelidotin (MICVO), in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The data show a 46% confirmed objective response rate (ORR) for MICVO as monotherapy and a 71% confirmed ORR when combined with KEYTRUDA. The drug demonstrated a 92% disease control rate and is well-tolerated among treated patients. Future updates from ongoing trials are anticipated in mid-2026 and the second half of 2026.
Read more →PYXS▲ +7%on this newsshared move
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
Pyxis Oncology has provided a business update and reported its financial results for Q3 2025. The company anticipates preliminary data from its Phase 1 studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma by the end of 2025. The updates include insights from recent presentations at major oncology conferences, emphasizing the potential of MICVO as a treatment option.
Read more →PYXS▼ -6.4%on this news
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Pyxis Oncology will present translational data on micvotabart pelidotin (MICVO) at ESMO 2025 and AACR-NCI-EORTC conferences. The data highlights MICVO's unique mechanism of action, which includes direct tumor cell killing and immune activation. The findings support ongoing clinical studies, particularly in head and neck squamous cell carcinoma.
Read more →About Pyxis Oncology, Inc.
Headquarters321 HARRISON AVENUE, BOSTON, MA, 02118
BIOPHARMAWATCH ELITE PLUS
Trade the next PYXS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime